ONVO Stock Performance, Insider Transaction and News

ONVO - Organovo Holdings, Inc.

Market Cap	14.38M	P/E	-	EPS this Y	40.00%	Ern Qtrly Grth	-
Income	-13.99M	Forward P/E	-7.86	EPS next Y	8.30%	50D Avg Chg	-6.00%
Sales	73k	PEG	-	EPS past 5Y	-	200D Avg Chg	-10.00%
Dividend	N/A	Price/Book	0.94	EPS next 5Y	-	52W High Chg	-56.00%
Recommedations	3.00	Quick Ratio	3.07	Shares Outstanding	15.36M	52W Low Chg	20.00%
Insider Own	2.02%	ROA	-73.67%	Shares Float	15.18M	Beta	0.61
Inst Own	15.15%	ROE	-151.72%	Shares Shorted/Prior	37.28K/141.35K	Price	1.65
Gross Margin	-	Profit Margin	-	Avg. Volume	23,632	Target Price	6.10
Oper. Margin	-8,682.05%	Earnings Date	Nov 7	Volume	15,506	Change	1.85%

Healthcare | Biotechnology | United States

About Organovo Holdings, Inc.

Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised of mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company's lead candidate is FXR314, which is phase 2/3 clinical trial for indication of inflammatory bowel disease with a clinical focus on ulcerative colitis; and completed phase 1 clinical trial for the indication of liver fibrosis with a clinical focus on non-alcoholic steatohepatitis and primary biliary cholangitis. It has research collaborations with Yale School of Medicine, Knight Cancer Institute at Oregon Health & Science University, and the University of Virginia for research of NovoGen Bioprinters. The company was incorporated in 2007 and is headquartered in San Diego, California.

Organovo Holdings, Inc. News

11/20/24	Organovo Presents Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting
11/13/24	Organovo to Present Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting Sponsored by the American Association for the Study of Liver Diseases
11/11/24	ONVO Releases Encouraging Quarterly Results
11/08/24	Organovo: Fiscal Q2 Earnings Snapshot
08/06/24	ONVO Announces Earnings and Notes Potential for Acquisition
07/16/24	Organovo Highlights FXR314 Near Term Value Catalysts at Jones Trading Conference Strong Preclinical and Human Rationale for FXR314 in P2 2 Ulcerative Colitis
06/04/24	ONVO Increases Cash and Improves Prospects
07:05 AM	Organovo Data Presented at Digestive Disease Week (DDW2024) Demonstrating Potential for FXR314 as Combination Therapy with Tofacitinib for Inflammatory Bowel Disease
05/14/24	Organovo to Present Data on FXR314 at Digestive Diseases Week (DDW2024)
05/08/24	Organovo Holdings, Inc. Announces Pricing of $5.25 Million Public Offering
05/01/24	ONVO Announces Very Positive Phase 2 Results
04/15/24	Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo
03/28/24	Top 15 3D Printing Companies in the US
02/10/24	Organovo Holdings Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
02/09/24	ONVO Continues Progress
01/25/24	Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn’s and Colitis Congress
01/09/24	Organovo To Present FXR314 IBD 3D Model Findings at Upcoming Crohn’s and Colitis Congress
12/06/23	Organovo Provides Timing for Release of FXR314 Phase 2 NASH Results

ONVO Chatroom

DjStockTrades Posted - 10 hours ago

WL for 11/21/24: $RELI $WORX $ONVO $SPAI $VMAR

StockRedBaron Posted - 1 day ago

$ONVO Great news! https://finance.yahoo.com/news/organovo-presents-clinical-data-fxr314-130500585.html

locobio Posted - 2 days ago

$ONVO Still an absolute scam. How can this still be listed?? Breakdown in oversight. Investors, beware!

First_Class_Seaman Posted - 3 days ago

$ZONE nice. Lot of nice DD here by the bulls and whales $ONVO volume picking up. Chart looking ready for another run

lucky9150 Posted - 1 week ago

$ONVO , 0n November 17th, they are presenting new data or old one from April 15th ?

RobsCrumpton Posted - 2 weeks ago

$ONVO anybody know when earnings is?

garygb Posted - 10/28/24

$ONVO wants to climb

DonCorleone77 Posted - 10/25/24

$ONVO Organovo files to sell common stock, warrants, no amount given Roth Capital Partners is managing the offering.

hitmongreen Posted - 1 month ago

$ONVO 👌

locobio Posted - 09/25/24

$ONVO No delisting notice yet?

PenkeTrading Posted - 09/24/24

I found you an Oversold RSI (Relative Strength Index) on the daily chart of Organovo Holdings Inc. Is that bullish or bearish? $ONVO #Organovo #RsiOversold #NASDAQ

Baboo15 Posted - 09/23/24

$ONVO pure shit!

MsGrumpy Posted - 2 months ago

$DDDX Several years ago, 3D Printing stocks started out with a bang but then fizzled. Now AI ChatGPT tells us that 3D printing stocks are back https://richardacavalli.wixsite.com/greenplanetmicrocaps/3d-printing-to-explode $DDD $NMDN $ONVO $VLD $MKFG

kits77 Posted - 2 months ago

Monthly deliveries of $NIO and $ONVO will be more than 35K starting January 2025 and more than 40K by March 2025. Swapping will be profitable by Q4 2025 and it generates a net profit of $50 million starting that quarter. And it explodes from Q1 2026. I am impressed with 20k deliveries especially when they launched ONVO. NIO successfully did what Toyota and Lexus did. Good job $NIO . Many taxi drivers buy Onvos. Swapping should be discounted by 50% during 12 AM and 6 AM. This will help breakeven faster as taxi drivers can Swap during those hours. This should be the mode at least until autonomous swapping during nights is enabled. The Swap should be determined by demand and supply. Swap fee should be 20% less at a PSS that has more charged batteries. Swap fee should be dynamic. For sure more positive changes coming. NIO Auto Insurance may be?

Catdaddy770 Posted - 3 months ago

$ONVO is this company still a scam or did they fix everything and a real company now? I rode the initial wave from $1 to $12 and waiting on Nasdaq and was surprised this was still going after the Cali bro CEO

kits77 Posted - 3 months ago

@jonny8d ASP of 32K between $NIO and $ONVO with a gross margin of 15%. 40K vehicle sales per month starting January 2025. I hope my numbers are very reasonable and seem to be reasonable especially when I heard Mr Li saying 100 million swaps next year. He is planning to achieve 1 million cumulative vehicle deliveries by end of Q3 2025. Easily achievable with 40K deliveries per month from Jan 2025. Aug/sep - 20K , Oct/Nov/Dec - 30k , Jan-Sep - 40K/month. As of July 31, 2024, Nio's cumulative deliveries have reached 557,518 vehicles. So , if we do math …557,518+40000(Aug&Sep)+90000 ( Oct -Dec) +320000 ( Jan - Sep 2025) =1,007518 vehicles. Market is going to witness huge growth within the next 2 quarters. SP will follow. Thanks

PenkeTrading Posted - 3 months ago

I found you an Oversold RSI (Relative Strength Index) on the daily chart of Organovo Holdings Inc. Is that bullish or bearish? $ONVO #ONVO #nasdaq #tradingsignals #technicalanalysis

NVDAMillionaire Posted - 3 months ago

$ONVO Organovo Holdings, Inc. (ONVO): Advancing Clinical Development of FXR314 and Building High-Fidelity 3D Tissue Models for Drug Discovery http://beyondspx.com/2024/08/01/organovo-holdings-inc-onvo-advancing-clinical-development-of-fxr314-and-building-high-fidelity-3d-tissue-models-for-drug-discovery/

locobio Posted - 07/31/24

$ONVO Did they get a delisting warning yet? Been down below 1.00 for weeks now.

jsnchris Posted - 07/23/24

$ONVO Eli Lilly Buys Morphic for $3.2B. Please..buys ONVO.....Fxr314....

jsnchris Posted - 07/23/24

$ONVO pr ? .....two weeks...

lousjamsession Posted - 07/23/24

$ONVO

TheBattleDude Posted - 07/22/24

$ONVO ohhh this looks scary but it time for me to jump in,

TheLearnerEarner Posted - 4 months ago

$ONVO added ADVENTUROUS stock swing trade - healthcare - micro cap - 1/9 F-Score - 1.16x relative volume - short term gains 💱 RSI: 24.95 (oversold) 📊 RISK: Adventurous 🌟 Range (12m) $0.55 - $2.05 💰 NEWSDESK (last recent article) 📰 https://www.stocktitan.net/news/ONVO/organovo-highlights-fxr314-near-term-value-catalysts-at-jones-c9pj0eg7y2t6.html